Understanding your biotech product? analytical and bio-analytical characterization.
Dates:
Wednesday
28th January 2009
Venue:
Radisson SAS
Portman Hotel
London, UK
Aims of the course
To ensure that delegates have the appropriate knowledge in the field of analytical and bioanalytical characterization to allow them to undertake their professional roles and specifically as follows:
• The techniques used to characterize biopharmaceutical medicinal products
• Regulatory requirements and expectations for characterisation data at different stages of the product development cycle
• Impact of process variables on product quality
• Requirements for comparability assessment following process changes
• Importance of characterisation techniques in a biosimilar product MAA.
Who should attend
The conference is designed for regulatory staff who are working with biotechnology-derived products, particularly those who may not have first hand manufacturing or process development experience, and those who are new to regulatory affairs. This conference would also be useful for anyone wishing to refresh his or her knowledge in the area.
Programme includes:
• Analytical characterisation concentrating on in vitro and biophysical techniques
• Bio-analytical techniques concentrating on bioassays and agency expectations for bioassays
• Impact of process variables on product quality
• Comparability assessment example following a major process change (a case study from Wyeth)
• Regulatory Agency perspective on comparability
• Biosimilars
Speakers include:
• Paul Chamberlain, Director, NDA Advisory Board, UK
• Brendan Fish, Director Bio-analytical Group, MedImmune, UK
• Brian Fitzpatrick, Associate Director of Analytical Development, Wyeth, Eire
• Stephen Fitzpatrick, Head of CMC RA, UCB Pharma Ltd, UK
• Kowid Ho, Biologicals/Biotechnology Unit, AFSSaPS, France
• Paul Jeffreys, Senior Manager RA, Eisai, UK
• Meg Leahey, Associate director, Wyeth Biotech, Eire
• Cecil Nick, Vice President, Parexel Consulting , UK
• Jane Robinson, NIBSC, UK
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.